デフォルト表紙
市場調査レポート
商品コード
1006056

薬剤溶出ステント (DES) 市場の成長機会・成長予測 (2020-2027年):コーティング・用途・エンドユーザー・地域別

Drug-Eluting Stents Market by Coating, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 198 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.12円
薬剤溶出ステント (DES) 市場の成長機会・成長予測 (2020-2027年):コーティング・用途・エンドユーザー・地域別
出版日: 2021年03月27日
発行: Allied Market Research
ページ情報: 英文 198 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の薬剤溶出ステント (DES) の市場規模は予測期間中8.7%のCAGRで推移し、2019年の63億8200万米ドルから、2027年には87億7700万米ドルの規模に成長すると予測されています。

糖尿病、肥満、高血圧の増加により、心血管疾患(CVD)、冠状動脈性心臓病、心不全の発症率が上昇していおり、予測期間中の市場成長が見込まれています。また、製品承認数の増加、ステント製造に使用されるポリマー技術の普及、政府による償還政策の増加などの要因が同市場の成長を推進しています。一方で、製品のリコールやリスクが市場のさらなる成長を抑制しています。

当レポートでは、世界の薬剤溶出ステント (DES) の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、コーティング・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターのファイブフォース分析
  • 主要企業の位置付け
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析
  • Covid-19:影響分析

第4章 市場分析・予測:コーティング別

  • 主要動向・成長要因・成長機会
  • 市場規模・予測:地域別
  • 市場分析:国別
  • 市場規模・予測:タイプ別
  • ポリマーベースのコーティング
    • 生分解性
    • 非生分解性
  • ポリマーフリーコーティング
    • 微細孔面
    • 微細構造表面
    • スロット付き管状面
    • ナノポーラス面

第5章 市場分析・予測:用途別

  • 市場規模・予測:地域別
  • 市場分析:国別
  • 冠動脈疾患
  • 末梢動脈疾患

第6章 市場分析・予測:エンドユーザー別

  • 市場規模・予測:地域別
  • 市場分析:国別
  • 病院
  • 外来手術センター
  • その他

第7章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ
    • 主要動向・成長要因・成長機会
    • 市場規模・予測:国別
    • LAMEAの市場規模・予測:コーティング別
    • LAMEAの市場規模・予測:用途別
    • LAMEAの市場規模・予測:エンドユーザー別

第8章 企業プロファイル

  • ABBOTT LABORATORIES
  • ALVIMEDICA
  • B. BRAUN HOLDING GMBH & CO. KG
  • BIOSENSORS INTERNATIONAL GROUP, LTD
  • BIOTRONIK, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • COOK GROUP (COOK MEDICAL)
  • MEDTRONIC PLC.
  • STENTYS SA
  • TERUMO CORPORATION
図表

LIST OF TABLES

  • TABLE 01.DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027 ($MILLION)
  • TABLE 02.POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 04.POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 06.DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 07.CORONARY ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.PERIPHERAL ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.DRUG-ELUTING STENTS MARKET, BY HOSPITALS, 2019-2027 ($MILLION)
  • TABLE 10.DRUG-ELUTING STENTS MARKET FOR HOSPITALS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.DRUG-ELUTING STENTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.DRUG-ELUTING STENTS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.DRUG-ELUTING STENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 15.U.S. DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 16.U.S. DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 17.U.S. DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 18.CANADA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 19.CANADA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 20.CANADA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 21.MEXICO DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 22.MEXICO DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 23.MEXICO DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 24.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 25.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 26.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 27.EUROPE DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 28.GERMANY DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 29.GERMANY DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 30.GERMANY DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 31.FRANCE DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 32.FRANCE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 33.FRANCE DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 34.UK DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 35.UK DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 36.UK DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 37.ITALY DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 38.ITALY DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 39.ITALY DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 40.SPAIN DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 41.SPAIN DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 42.SPAIN DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 43.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 44.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 45.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 46.EUROPE DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 47.EUROPE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 48.EUROPE DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 49.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 50.CHINA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 51.CHINA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 52.CHINA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 53.JAPAN DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 54.JAPAN DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 55.JAPAN DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 56.INDIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 57.INDIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 58.INDIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 59.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 60.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 61.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 62.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 63.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 64.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 65.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 66.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 67.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 68.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 69.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 70.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 71.LAMEA DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 72.BRAZIL DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 73.BRAZIL DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 74.BRAZIL DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 75.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 76.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 77.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 78.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 79.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 80.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 81.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 82.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 83.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 84.LAMEA DRUG-ELUTING STENTS MARKET, BY COATING, 2019-2027
  • TABLE 85.LAMEA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019-2027
  • TABLE 86.LAMEA DRUG-ELUTING STENTS MARKET, BY END USER, 2019-2027
  • TABLE 87.ABBOTT: COMPANY SNAPSHOT
  • TABLE 88.ABBOTT: OERATING SEGMENT
  • TABLE 89.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 90.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91.ALVIMEDICA: COMPANY SNAPSHOT
  • TABLE 92.ALVIMEDICA: PRODUCT PORTFOLIO
  • TABLE 93.ALVIMEDICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94.B BRAUN: COMPANY SNAPSHOT
  • TABLE 95.B BRAUN: OPERATING SEGMENTS
  • TABLE 96.B BRAUN: PRODUCT PORTFOLIO
  • TABLE 97.BIOSENSORS INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 98.BIOSENSORS INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 99.BIOSENSORS INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100.BIOTRONIK: COMPANY SNAPSHOT
  • TABLE 101.BIOTRONIK: OPERATING SEGMENTS
  • TABLE 102.BIOTRONIK: PRODUCT PORTFOLIO
  • TABLE 103.BIOTRONIK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104.BOSTON: COMPANY SNAPSHOT
  • TABLE 105.BOSTON: OPERATING SEGMENTS
  • TABLE 106.BOSTON: PRODUCT PORTFOLIO
  • TABLE 107.COOK: COMPANY SNAPSHOT
  • TABLE 108.COOK: OPERATING SEGMENTS
  • TABLE 109.COOK: PRODUCT PORTFOLIO
  • TABLE 110.COOK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111.MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 112.MEDTRONIC: OPERATING SEGMENTS
  • TABLE 113.MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 114.MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115.STENTYS: COMPANY SNAPSHOT
  • TABLE 116.STENTYS: PRODUCT PORTFOLIO
  • TABLE 117.TERUMO: COMPANY SNAPSHOT
  • TABLE 118.TERUMO: OERATING SEGMENT
  • TABLE 119.TERUMO: PRODUCT PORTFOLIO
  • TABLE 120.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.DRUG-ELUTING STENTS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.HIGH THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2019
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 14.BIODEGRADABLE POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 15.NON-BIODEGRADABLE POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 17.MICROPOROUS SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 18.MICROSTRUCTURED SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 19.SLOTTED TUBULAR SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 20.NANOPOROUS SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019-2027, ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF PERIPHERAL ARTERY DISEASE DRUG-ELUTING STENTS MARKET, 2019 & 2027 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 26.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 27.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 29.B BRAUN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 30.B BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 31.B BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 32.BOSTON: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 33.BOSTON: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 34.BOSTON: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 35.MEDTRONIC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 37.MEDTRONIC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 38.STENTYS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 39.STENTYS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 40.TERUMO: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 41.TERUMO: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 42.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
目次
Product Code: LI_2110969 / A10604

The global drug-eluting stents market was valued at $6,382 million in 2019, and is projected to reach $8,777 million by 2027, registering a CAGR of 8.7% from 2020 to 2027.

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages. They are usually used in the treatment of percutaneous coronary intervention or coronary angioplasty. There are two types of DES available, namely, polymer-based coating DES and polymer free coating DES. Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries. They are used in coronary artery disease and peripheral artery disease.

Increase in prevalence of diabetes, obesity, and high blood pressure worldwide have led to rise in incidences of cardiovascular diseases (CVD), coronary heart disease, and heart failure. This, in turn, is expected to boost growth of the drug-eluting stents market during the forecast period. In addition, surge in number of product approvals, rise in popularity of polymer technology for production of stents, and surge in reimbursement policies supported by governments are the key factors that fuel growth of the global drug-eluting stents market. Moreover, rise in geriatric population propels growth of the market as geriatric population is at high risk of developing arterial disorders. However, product recall and risks associated with DES restricts growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

The global drug-eluting stents market is segmented on the basis of coating, application, end user, and region. On the basis of coating, the market is divided into polymer-based coating and polymer free coating. The polymer-based coating segment is further bifurcated into biodegradable and non-biodegradable. The polymer free coating segment is further divided into microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface. By application, the market is categorized into coronary artery disease and peripheral artery disease. By end user, the market is bifurcated into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Coating

  • Polymer-Based Coating
  • Biodegradable
  • Non-Biodegradable
  • Polymer Free Coating
  • Microporous Surface
  • Microstructured Surface
  • Slotted Tubular Surface
  • Nanoporous Surface

By Application

  • Coronary Artery Disease
  • Peripheral Artery Disease

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Alvimedica
  • B. Braun Holding GmbH & Co. KG
  • Biosensors International Group
  • Biotronik Inc.
  • Boston Scientific Corporation
  • Cook Group (Cook Medical)
  • Medtronic Plc
  • Stentys SA
  • Terumo Corporation.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Lepu Medical Technology
  • Shandong JW Medical Systems
  • MicroPort Scientific Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in prevalence of cardiovascular disease
      • 3.5.1.2.Surge in demand for minimally invasive surgical procedures
      • 3.5.1.3.Introduction of advanced drug eluting stents
    • 3.5.2.Restraint
      • 3.5.2.1.Stringent government regulations
    • 3.5.3.Opportunities
      • 3.5.3.1.Growth opportunities in emerging markets
    • 3.5.4.Impact analysis
  • 3.6.Covid-19 Impact analysis on drug-eluting stents market

CHAPTER 4:DRUG-ELUTING STENTS MARKET, BY COATING

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Polymer based coating
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Market size and forecast, by type
    • 4.2.5.Biodegradable
      • 4.2.5.1.Market size and forecast
    • 4.2.6.Non-biodegradable
      • 4.2.6.1.Market size and forecast
  • 4.3.Polymer free coating
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
    • 4.3.4.Market size and forecast, by type
    • 4.3.5.Microporous surface
      • 4.3.5.1.Market size and forecast
    • 4.3.6.Microstructured surface
      • 4.3.6.1.Market size and forecast
    • 4.3.7.Slotted tubular surface
      • 4.3.7.1.Market size and forecast
    • 4.3.8.Nanoporous surface
      • 4.3.8.1.Market size and forecast

CHAPTER 5:DRUG-ELUTING STENTS MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Coronary artery disease
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Peripheral artery disease
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:DRUG-ELUTING STENTS MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospitals
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Ambulatory surgical centers
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Others
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:DRUG-ELUTING STENTS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. drug-eluting stents market, by coating
      • 7.2.2.1.2.U.S. drug-eluting stents market, by application
      • 7.2.2.1.3.U.S. drug-eluting stents market, by end user
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada drug-eluting stents market, by coating
      • 7.2.2.2.2.Canada drug-eluting stents market, by application
      • 7.2.2.2.3.Canada drug-eluting stents market, by end user
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico drug-eluting stents market, by coating
      • 7.2.2.3.2.Mexico drug-eluting stents market, by application
      • 7.2.2.3.3.Mexico drug-eluting stents market, by end user
    • 7.2.3.North America market size and forecast, by coating
    • 7.2.4.North America market size and forecast, by application
    • 7.2.5.North America market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany drug-eluting stents market, by coating
      • 7.3.2.1.2.Germany drug-eluting stents market, by application
      • 7.3.2.1.3.Germany drug-eluting stents market, by end user
      • 7.3.2.2.France
      • 7.3.2.2.1.France drug-eluting stents market, by coating
      • 7.3.2.2.2.France drug-eluting stents market, by application
      • 7.3.2.2.3.France drug-eluting stents market, by end user
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK drug-eluting stents market, by coating
      • 7.3.2.3.2.UK drug-eluting stents market, by application
      • 7.3.2.3.3.UK drug-eluting stents market, by end user
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy drug-eluting stents market, by coating
      • 7.3.2.4.2.Italy drug-eluting stents market, by application
      • 7.3.2.4.3.Italy drug-eluting stents market, by end user
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain drug-eluting stents market, by coating
      • 7.3.2.5.2.Spain drug-eluting stents market, by application
      • 7.3.2.5.3.Spain drug-eluting stents market, by end user
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe drug-eluting stents market, by coating
      • 7.3.2.6.2.Rest of Europe drug-eluting stents market, by application
      • 7.3.2.6.3.Rest of Europe drug-eluting stents market, by end user
    • 7.3.3.Europe market size and forecast, by coating
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.China
      • 7.4.2.1.1.China drug-eluting stents market, by coating
      • 7.4.2.1.2.China drug-eluting stents market, by application
      • 7.4.2.1.3.China drug-eluting stents market, by end user
      • 7.4.2.2.Japan
      • 7.4.2.2.1.Japan drug-eluting stents market, by coating
      • 7.4.2.2.2.Japan drug-eluting stents market, by application
      • 7.4.2.2.3.Japan drug-eluting stents market, by end user
      • 7.4.2.3.India
      • 7.4.2.3.1.India drug-eluting stents market, by coating
      • 7.4.2.3.2.India drug-eluting stents market, by application
      • 7.4.2.3.3.India drug-eluting stents market, by end user
      • 7.4.2.4.Australia
      • 7.4.2.4.1.Australia drug-eluting stents market, by coating
      • 7.4.2.4.2.Australia drug-eluting stents market, by application
      • 7.4.2.4.3.Australia drug-eluting stents market, by end user
      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea drug-eluting stents market, by coating
      • 7.4.2.5.2.South Korea drug-eluting stents market, by application
      • 7.4.2.5.3.South Korea drug-eluting stents market, by end user
      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific drug-eluting stents market, by coating
      • 7.4.2.6.2.Rest of Asia-Pacific drug-eluting stents market, by application
      • 7.4.2.6.3.Rest of Asia-Pacific drug-eluting stents market, by end user
    • 7.4.3.Asia-Pacific market size and forecast, by coating
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil drug-eluting stents market, by coating
      • 7.5.2.1.2.Brazil drug-eluting stents market, by application
      • 7.5.2.1.3.Brazil drug-eluting stents market, by end user
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia drug-eluting stents market, by coating
      • 7.5.2.2.2.Saudi Arabia drug-eluting stents market, by application
      • 7.5.2.2.3.Saudi Arabia drug-eluting stents market, by end user
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa drug-eluting stents market, by coating
      • 7.5.2.3.2.South Africa drug-eluting stents market, by application
      • 7.5.2.3.3.South Africa drug-eluting stents market, by end user
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA drug-eluting stents market, by coating
      • 7.5.2.4.2.Rest of LAMEA drug-eluting stents market, by application
      • 7.5.2.4.3.Rest of LAMEA drug-eluting stents market, by end user
    • 7.5.3.LAMEA market size and forecast, by coating
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.ALVIMEDICA
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Key strategic moves and developments
  • 8.3.B. BRAUN HOLDING GMBH & CO. KG
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.BIOSENSORS INTERNATIONAL GROUP, LTD
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Key strategic moves and developments
  • 8.5.BIOTRONIK, INC.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Key strategic moves and developments
  • 8.6.BOSTON SCIENTIFIC CORPORATION
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.COOK GROUP (COOK MEDICAL)
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Key strategic moves and developments
  • 8.8.MEDTRONIC PLC.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.STENTYS SA
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.TERUMO CORPORATION
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments